BlueCross BlueShield Arizona

An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 12/19/23**
SECTION: SURGERY	**LAST REVIEW DATE: 06/18/24**
	CURRENT EFFECTIVE DATE: 06/18/24
	LAST CRITERIA REVISION DATE:
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 12/19/23
LAST REVIEW DATE: 06/18/24
CURRENT EFFECTIVE DATE: 06/18/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 2ND QTR 2025

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Description:

Damaged articular cartilage typically fails to heal on its own and can be associated with pain, loss of function, and disability, and may lead to debilitating osteoarthritis over time. These manifestations can severely impair an individual's activities of daily living and adversely affect quality of life.

A variety of procedures are being developed to resurface articular cartilage defects. Autologous chondrocyte implantation involves harvesting chondrocytes from healthy tissue, expanding the cells in vitro, and implanting the expanded cells into the chondral defect. Second- and third-generation techniques include combinations of autologous chondrocytes, scaffolds, and growth factors.

With autologous chondrocyte implantation, a region of healthy articular cartilage is identified and biopsied through arthroscopy. The tissue is sent to a facility licensed by the U.S. Food and Drug Administration (FDA) where it is minced and enzymatically digested, and the chondrocytes are separated by filtration. The isolated chondrocytes are cultured for 11 to 21 days to expand the cell population, tested, and then shipped back for implantation. With the individual under general anesthesia, an arthrotomy is performed, and the chondral lesion is excised up to the normal surrounding cartilage. Methods to improve the first-generation autologous chondrocyte implantation procedure have been developed, including the use of a scaffold or matrix-induced autologous chondrocyte implantation composed of biocompatible carbohydrates, protein polymers, or synthetics. The only FDA approved matrix-induced autologous chondrocyte implantation product to date is supplied in a sheet, which is cut to size and fixed with fibrin glue. This procedure is considered technically easier and less time-consuming than the first-generation technique, which required suturing of a periosteal or collagen patch and injection of chondrocytes under the patch.

The culturing of chondrocytes is considered by the FDA to fall into the category of manipulated autologous structural cells, which are subject to a biologic licensing requirement.

FDA-approved products include, but are not limited to, the following:

- Agili-C
- Carticel® (Genzyme; now Vericel)
- MACI® (Vericel)

A number of other second-generation methods for implanting autologous chondrocytes in a biodegradable matrix are currently in development or testing or are available outside of the United States. They include Atelocollagen (Koken), a collagen gel; Bioseed® C (BioTissue Technologies), a polymer scaffold; CaReS (Ars Arthro), collagen gel; Cartilix (Biomet), a polymer hydrogel; Chondron (Sewon Cellontech), a fibrin gel; Hyalograft C (Fidia Advanced Polymers), a hyaluronic acid-based scaffold; NeoCart (Histogenics), an autologous chondrocyte implantation with a 3-dimensional chondromatrix in a phase 3 trial; and Novocart®3D (Aesculap Biologics), a collagen-chondroitin sulfate scaffold in a phase 3 trial. ChondroCelect® (TiGenix), characterized as a chondrocyte implantation with a completed phase 3 trial, uses a gene marker profile to determine in vivo cartilage-forming potential and thereby optimizes the phenotype (e.g., hyaline cartilage vs. fibrocartilage) of the tissue produced with each autologous chondrocyte implantation cell batch. Each batch of chondrocytes is graded based on the quantitative

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

gene expression of a selection of positive and negative markers for hyaline cartilage formation. Both Hyalograft C and ChondroCelect have been withdrawn from the market in Europe.

In 2020, the FDA granted breakthrough status to Agili-CTM (CartiHeal, Ltd.), a proprietary cell-free biocompatible and biodegradable tapered-shape implant for the treatment of cartilage lesions in arthritic and non-arthritic joints that, when implanted into a pre-prepared osteochondral hole, acts as a 3-dimensional scaffold that potentially supports and promotes the regeneration of the articular cartilage and its underlying subchondral bone.

Criteria:

- Autologous chondrocyte implantation for the treatment of disabling full-thickness articular cartilage defects of the knee caused by acute or repetitive trauma is considered ***medically necessary*** with documentation of **ALL** of the following:

  1. Adolescent individuals should be skeletally mature with documented closure of growth plates (e.g., ≥15 years). Adult individuals should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., <55 years)

  2. Focal, full-thickness (grade III or IV) unipolar lesions of the weight-bearing surface of the femoral condyles, trochlea, or patella at least 1.5 cm^2 in size

  3. Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect

  4. Normal knee biomechanics or alignment and stability achieved concurrently with autologous chondrocyte implantation.

- Autologous chondrocyte implantation for all other indications not previously listed or if above criteria not met is considered ***experimental or investigational*** when any **ONE** or more of the following criteria are met:

  1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
  2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
  3. Insufficient evidence to support improvement of the net health outcome; or
  4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, or
  5. Insufficient evidence to support improvement outside the investigational setting.

  These indications include, but are not limited to:

  - All other joints, including the talar

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Resources:

Literature reviewed 06/18/24. We do not include marketing materials, poster boards and non-published literature in our review.

1. Abraamyan T, Johnson AJ, Wiedrick J, Crawford DC. Marrow Stimulation Has Relatively Inferior Patient-Reported Outcomes in Cartilage Restoration Surgery of the Knee: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Am J Sports Med*. Mar 2022;50(3):858-866. doi:10.1177/03635465211003595

2. Agili-C – P210034. U.S. Food and Drug Administration. Updated April 29, 2022. Accessed February 20, 2023. https://www.fda.gov/medical-devices/recently-approved-devices/agili-c-p210034

3. American Academy of Orthopaedic Surgeons. Clinical Practice Guideline on the Diagnosis and Treatment of Osteochondritis Dissecans. AAOS. 2010. Updated December 1, 2023. Accessed February 20, 2024. https://www.orthoguidelines.org/guidelines

4. Andriolo L, Merli G, Filardo G, Marcacci M, Kon E. Failure of Autologous Chondrocyte Implantation. *Sports Med Arthrosc Rev*. Mar 2017;25(1):10-18. doi:10.1097/JSA.0000000000000137

5. Angele P, Zellner J, Schroter S, Flechtenmacher J, Fritz J, Niemeyer P. Biological Reconstruction of Localized Full-Thickness Cartilage Defects of the Knee: A Systematic Review of Level 1 Studies with a Minimum Follow-Up of 5 Years. *Cartilage*. Dec 2022;13(4):5-18. doi:10.1177/19476035221129571

6. Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. *J Bone Joint Surg Br*. May 2005;87(5):640-5. doi:10.1302/0301-620X.87B5.15905

7. Basad E, Ishaque B, Bachmann G, Sturz H, Steinmeyer J. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc*. Apr 2010;18(4):519-27. doi:10.1007/s00167-009-1028-1

8. Basad E, Wissing FR, Fehrenbach P, Rickert M, Steinmeyer J, Ishaque B. Matrix-induced autologous chondrocyte implantation (MACI) in the knee: clinical outcomes and challenges. *Knee Surg Sports Traumatol Arthrosc*. Dec 2015;23(12):3729-35. doi:10.1007/s00167-014-3295-8

9. Bin Abd Razak HR, Acharyya S, Tan SM, et al. Predictors of Midterm Outcomes after Medial Unicompartmental Knee Arthroplasty in Asians. *Clin Orthop Surg*. Dec 2017;9(4):432-438. doi:10.4055/cios.2017.9.4.432

10. Brittberg M, Recker D, Ilgenfritz J, Saris DBF, Group SES. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial. *Am J Sports Med*. May 2018;46(6):1343-1351. doi:10.1177/0363546518756976

11. Clement ND, MacDonald D, Simpson AH. The minimal clinically important difference in the Oxford knee score and Short Form 12 score after total knee arthroplasty. *Knee Surg Sports Traumatol Arthrosc*. Aug 2014;22(8):1933-9. doi:10.1007/s00167-013-2776-5

12. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). *Arthritis Care Res (Hoboken)*. Nov 2011;63 Suppl 11(0 11):S208-28. doi:10.1002/acr.20632

13. Copay AG, Eyberg B, Chung AS, Zurcher KS, Chutkan N, Spangehl MJ. Minimum Clinically Important Difference: Current Trends in the Orthopaedic Literature, Part II: Lower Extremity: A Systematic Review. *JBJS Rev*. Sep 2018;6(9):e2. doi:10.2106/JBJS.RVW.17.00160

14. Devitt BM, Bell SW, Webster KE, Feller JA, Whitehead TS. Surgical treatments of cartilage defects of the knee: Systematic review of randomised controlled trials. *Knee*. Jun 2017;24(3):508-517. doi:10.1016/j.knee.2016.12.002

15. Dhillon J, Decilveo AP, Kraeutler MJ, Belk JW, McCulloch PC, Scillia AJ. Third-Generation Autologous Chondrocyte Implantation (Cells Cultured Within Collagen Membrane) Is Superior to Microfracture for Focal Chondral Defects of the Knee Joint: Systematic Review and Meta-analysis. *Arthroscopy*. Aug 2022;38(8):2579-2586. doi:10.1016/j.arthro.2022.02.011

16. Ebert JR, Fallon M, Wood DJ, Janes GC. A Prospective Clinical and Radiological Evaluation at 5 Years After Arthroscopic Matrix-Induced Autologous Chondrocyte Implantation. *Am J Sports Med*. Jan 2017;45(1):59-69. doi:10.1177/0363546516663493

17. Ebert JR, Fallon M, Zheng MH, Wood DJ, Ackland TR. A randomized trial comparing accelerated and traditional approaches to postoperative weightbearing rehabilitation after matrix-induced autologous chondrocyte implantation: findings at 5 years. *Am J Sports Med*. Jul 2012;40(7):1527-37. doi:10.1177/0363546512445167

18. Ebert JR, Schneider A, Fallon M, Wood DJ, Janes GC. A Comparison of 2-Year Outcomes in Patients Undergoing Tibiofemoral or Patellofemoral Matrix-Induced Autologous Chondrocyte Implantation. *Am J Sports Med*. Dec 2017;45(14):3243-3253. doi:10.1177/0363546517724761

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

19. Ebert JR, Smith A, Edwards PK, Hambly K, Wood DJ, Ackland TR. Factors predictive of outcome 5 years after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint. *Am J Sports Med*. Jun 2013;41(6):1245-54. doi:10.1177/0363546513484696

20. Ebert JR, Smith A, Fallon M, et al. Incidence, degree, and development of graft hypertrophy 24 months after matrix-induced autologous chondrocyte implantation: association with clinical outcomes. *Am J Sports Med*. Sep 2015;43(9):2208-15. doi:10.1177/0363546515591257

21. Gou GH, Tseng FJ, Wang SH, et al. Autologous Chondrocyte Implantation Versus Microfracture in the Knee: A Meta-analysis and Systematic Review. *Arthroscopy*. Jan 2020;36(1):289-303. doi:10.1016/j.arthro.2019.06.033

22. Greco NJ, Anderson AF, Mann BJ, et al. Responsiveness of the International Knee Documentation Committee Subjective Knee Form in comparison to the Western Ontario and McMaster Universities Osteoarthritis Index, modified Cincinnati Knee Rating System, and Short Form 36 in patients with focal articular cartilage defects. *Am J Sports Med*. May 2010;38(5):891-902. doi:10.1177/0363546509354163

23. Gusi N OP, Rajendram R. The EQ-5D Health-Related Quality of Life Questionnaire [Abstract]. In: Preedy VR WR, eds. *Handbook of Disease Burdens and Quality of Life Measures*. Springer, New York; 2010:87-89.

24. Harris JD, Cavo M, Brophy R, Siston R, Flanigan D. Biological knee reconstruction: a systematic review of combined meniscal allograft transplantation and cartilage repair or restoration. *Arthroscopy*. Mar 2011;27(3):409-18. doi:10.1016/j.arthro.2010.08.007

25. Harris JD, Siston RA, Pan X, Flanigan DC. Autologous chondrocyte implantation: a systematic review. *J Bone Joint Surg Am*. Sep 15 2010;92(12):2220-33. doi:10.2106/JBJS.J.00049

26. Hoburg A, Niemeyer P, Laute V, et al. Sustained superiority in KOOS subscores after matrix-associated chondrocyte implantation using spheroids compared to microfracture. *Knee Surg Sports Traumatol Arthrosc*. Jun 2023;31(6):2482-2493. doi:10.1007/s00167-022-07194-x

27. Hu M, Li X, Xu X. Efficacy and safety of autologous chondrocyte implantation for osteochondral defects of the talus: a systematic review and meta-analysis. *Arch Orthop Trauma Surg*. Jan 2023;143(1):71-79. doi:10.1007/s00402-021-03990-1

28. Krueger DR, Baur ADJ, Perka C, Schroeder JH. Injectable autologous chondrocyte implantation in acetabular cartilage defects: 2-year minimum clinical and MRI results. *Arch Orthop Trauma Surg*. Feb 2023;143(2):739-747. doi:10.1007/s00402-021-04141-2

29. Lee WC, Bin Abd Razak HR, Allen JC, Chong HC, Tan HCA. Achieving Minimum Clinically Important Difference in Oxford Knee Score and Short Form-36 Physical Component Summary Is Less Likely with Single-Radius Compared with Multiradius Total Knee Arthroplasty in Asians. *J Knee Surg*. Mar 2019;32(3):227-232. doi:10.1055/s-0038-1641139

30. Lee WC, Kwan YH, Chong HC, Yeo SJ. The minimal clinically important difference for Knee Society Clinical Rating System after total knee arthroplasty for primary osteoarthritis. *Knee Surg Sports Traumatol Arthrosc*. Nov 2017;25(11):3354-3359. doi:10.1007/s00167-016-4208-9

31. MACI (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane). U.S. Food and Drug Administration. Updated June 30, 2021. Accessed February 20, 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane

32. Makris EA, Gomoll AH, Malizos KN, Hu JC, Athanasiou KA. Repair and tissue engineering techniques for articular cartilage. *Nat Rev Rheumatol*. Jan 2015;11(1):21-34. doi:10.1038/nrrheum.2014.157

33. Meyerkort D, Ebert JR, Ackland TR, et al. Matrix-induced autologous chondrocyte implantation (MACI) for chondral defects in the patellofemoral joint. *Knee Surg Sports Traumatol Arthrosc*. Oct 2014;22(10):2522-30. doi:10.1007/s00167-014-3046-x

34. Migliorini F, Eschweiler J, Gotze C, Driessen A, Tingart M, Maffulli N. Matrix-induced autologous chondrocyte implantation (mACI) versus autologous matrix-induced chondrogenesis (AMIC) for chondral defects of the knee: a systematic review. *Br Med Bull*. Mar 21 2022;141(1):47-59. doi:10.1093/bmb/ldac004

35. Migliorini F, Maffulli N, Schenker H, et al. Surgical Management of Focal Chondral Defects of the Talus: A Bayesian Network Meta-analysis. *Am J Sports Med*. Aug 2022;50(10):2853-2859. doi:10.1177/03635465211029642

36. Minas T, Gomoll AH, Rosenberger R, Royce RO, Bryant T. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med*. May 2009;37(5):902-8. doi:10.1177/0363546508330137

37. Minas T, Von Keudell A, Bryant T, Gomoll AH. The John Insall Award: A minimum 10-year outcome study of autologous chondrocyte implantation. *Clin Orthop Relat Res*. Jan 2014;472(1):41-51. doi:10.1007/s11999-013-3146-9

38. Mundi R, Bedi A, Chow L, et al. Cartilage Restoration of the Knee: A Systematic Review and Meta-analysis of Level 1 Studies. *Am J Sports Med*. Jul 2016;44(7):1888-95. doi:10.1177/0363546515589167

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

39. National Institute for Health and Care Excellence (NICE). Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee [TA508]. 2018. Accessed February 20, 2024. https://www.nice.org.uk/guidance/ta508

40. Nawaz SZ, Bentley G, Briggs TW, et al. Autologous chondrocyte implantation in the knee: mid-term to long-term results. *J Bone Joint Surg Am*. May 21 2014;96(10):824-30. doi:10.2106/JBJS.L.01695

41. Niemeyer P, Laute V, Zinser W, et al. A Prospective, Randomized, Open-Label, Multicenter, Phase III Noninferiority Trial to Compare the Clinical Efficacy of Matrix-Associated Autologous Chondrocyte Implantation With Spheroid Technology Versus Arthroscopic Microfracture for Cartilage Defects of the Knee. *Orthop J Sports Med*. Jul 2019;7(7):2325967119854442. doi:10.1177/2325967119854442

42. Niemeyer P, Pestka JM, Kreuz PC, et al. Characteristic complications after autologous chondrocyte implantation for cartilage defects of the knee joint. *Am J Sports Med*. Nov 2008;36(11):2091-9. doi:10.1177/0363546508322131

43. Niemeyer P, Salzmann G, Schmal H, Mayr H, Sudkamp NP. Autologous chondrocyte implantation for the treatment of chondral and osteochondral defects of the talus: a meta-analysis of available evidence. *Knee Surg Sports Traumatol Arthrosc*. Sep 2012;20(9):1696-703. doi:10.1007/s00167-011-1729-0

44. OrthoToolKit. Free Online Modified Cincinnati Knee Rating System Calculator -- OrthoToolKit. Accessed February 20, 2024. https://www.orthotoolkit.com/cincinnati/

45. Riboh JC, Cvetanovich GL, Cole BJ, Yanke AB. Comparative efficacy of cartilage repair procedures in the knee: a network meta-analysis. *Knee Surg Sports Traumatol Arthrosc*. Dec 2017;25(12):3786-3799. doi:10.1007/s00167-016-4300-1

46. Roos EM, Engelhart L, Ranstam J, et al. ICRS Recommendation Document: Patient-Reported Outcome Instruments for Use in Patients with Articular Cartilage Defects. *Cartilage*. Apr 2011;2(2):122-36. doi:10.1177/1947603510391084

47. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. *Health Qual Life Outcomes*. Nov 3 2003;1:64. doi:10.1186/1477-7525-1-64

48. Sacolick DA, Kirven JC, Abouljoud MM, Everhart JS, Flanigan DC. The Treatment of Adult Osteochondritis Dissecans with Autologous Cartilage Implantation: A Systematic Review. *J Knee Surg*. Nov 2019;32(11):1102-1110. doi:10.1055/s-0038-1675568

49. Saris D, Price A, Widuchowski W, et al. Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial. *Am J Sports Med*. Jun 2014;42(6):1384-94. doi:10.1177/0363546514528093

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

50. Schuette HB, Kraeutler MJ, McCarty EC. Matrix-Assisted Autologous Chondrocyte Transplantation in the Knee: A Systematic Review of Mid- to Long-Term Clinical Outcomes. *Orthop J Sports Med*. Jun 2017;5(6):2325967117709250. doi:10.1177/2325967117709250

51. Seiferth NL, Faber SO, Angele P, et al. Effect of Previous Knee Surgery on Clinical Outcome After ACI for Knee Cartilage Defects: A Propensity Score-Matched Study Based on the German Cartilage Registry (KnorpelRegister DGOU). *Am J Sports Med*. Mar 2022;50(4):994-1005. doi:10.1177/03635465211070536

52. Shimozono Y, Yasui Y, Ross AW, Miyamoto W, Kennedy JG. Scaffolds based therapy for osteochondral lesions of the talus: A systematic review. *World J Orthop*. Oct 18 2017;8(10):798-808. doi:10.5312/wjo.v8.i10.798

53. Simon TM, Jackson DW. Articular Cartilage: Injury Pathways and Treatment Options. *Sports Med Arthrosc Rev*. Mar 2018;26(1):31-39. doi:10.1097/JSA.0000000000000182

54. Vijayan S, Bartlett W, Bentley G, et al. Autologous chondrocyte implantation for osteochondral lesions in the knee using a bilayer collagen membrane and bone graft: a two- to eight-year follow-up study. *J Bone Joint Surg Br*. Apr 2012;94(4):488-92. doi:10.1302/0301-620X.94B4.27117

55. Zak L, Aldrian S, Wondrasch B, Albrecht C, Marlovits S. Ability to return to sports 5 years after matrix-associated autologous chondrocyte transplantation in an average population of active patients. *Am J Sports Med*. Dec 2012;40(12):2815-21. doi:10.1177/0363546512462382

56. Zamborsky R, Danisovic L. Surgical Techniques for Knee Cartilage Repair: An Updated Large-Scale Systematic Review and Network Meta-analysis of Randomized Controlled Trials. *Arthroscopy*. Mar 2020;36(3):845-858. doi:10.1016/j.arthro.2019.11.096

Coding:

CPT: 27412, 29870, 29871, 29873, 29874, 29875, 29876, 29877, 29879, 29880, 29881, 29882, 29883, 29884, 29885, 29886, 29887
HCPCS: J7330, S2112

History:	Date:	Activity:
Medical Policy Panel	06/18/24	Review with revisions
Medical Policy Panel	12/19/23	Approved guideline

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

NEXT ANNUAL REVIEW DATE: 2ND QTR 2025

ORIGINAL EFFECTIVE DATE: 12/19/23
LAST REVIEW DATE: 06/18/24
CURRENT EFFECTIVE DATE: 06/18/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Policy Revisions:

06/18/24	Updated	Resources section

BlueCross BlueShield Arizona

An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA	**ORIGINAL EFFECTIVE DATE: 12/19/23**
SECTION: SURGERY	**LAST REVIEW DATE: 06/18/24**
	CURRENT EFFECTIVE DATE: 06/18/24
	LAST CRITERIA REVISION DATE:
NEXT ANNUAL REVIEW DATE: 2ND QTR 2025	**ARCHIVE DATE:**

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1–800–368–1019, 800–537–7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nílínigíí Blue Cross Blue Shield of Arizona haada yit'éego bína'ídíłkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yína'ídíłkidgo beehaz'áanii hólǫ díí t'áá hazaadk'ehjí háká a'doowołgo bee haz'ą doo bąąh íłínígóó. Ata' halne'ígíí kojį' bich'į' hodíilnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:
إن كان لديك أو لدى شخص تساعده أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون اية تكلفة. للتحدث مع مترجم اتصل ب 877-475-4799.

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

NEXT ANNUAL REVIEW DATE: 2ND QTR 2025

ORIGINAL EFFECTIVE DATE: 12/19/23
LAST REVIEW DATE: 06/18/24
CURRENT EFFECTIVE DATE: 06/18/24
LAST CRITERIA REVISION DATE:
ARCHIVE DATE:

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

Multi-Language Interpreter Services:

Tagalog: Kung ikaw, o ang iyong tinutulangan, ay may mga katanungan tungkol sa Blue Cross Blue Shield of Arizona, may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika ng walang gastos. Upang makausap ang isang tagasalin, tumawag sa 877-475-4799.

Korean: 만약 귀하 또는 귀하가 돕고 있는 어떤 사람이 Blue Cross Blue Shield of Arizona 에 관해서 질문이 있다면 귀하는 그러한 도움과 정보를 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 그렇게 통역사와 얘기하기 위해서는 877-475-4799 로 전화하십시오.

French: Si vous, ou quelqu'un que vous êtes en train d'aider, a des questions à propos de Blue Cross Blue Shield of Arizona, vous avez le droit d'obtenir de l'aide et l'information dans votre langue à aucun coût. Pour parler à un interprète, appelez 877-475-4799.

German: Falls Sie oder jemand, dem Sie helfen, Fragen zum Blue Cross Blue Shield of Arizona haben, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer 877-475-4799 an.

Russian: Если у вас или лица, которому вы помогаете, имеются вопросы по поводу Blue Cross Blue Shield of Arizona, то вы имеете право на бесплатное получение помощи и информации на вашем языке. Для разговора с переводчиком позвоните по телефону 877-475-4799.

Japanese: ご本人様、またはお客様の身の回りの方でも、Blue Cross Blue Shield of Arizona についてご質問がございましたら、ご希望の言語でサポートを受けたり、情報を入手したりすることができます。料金はかかりません。通訳とお話される場合、877-475-4799 までお電話ください。

Farsi:
اگر شما، یا کسی که شما به او کمک میکنید ، سوال در مورد Blue Cross Blue Shield of Arizona ، داشته باشید حق این را دارید که کمک و اطلاعات به زبان خود را به طور رایگان دریافت نمایید 877-475-4799
[تماس حاصل نمایید.

Assyrian:
[illegible] Blue Cross Blue Shield of Arizona [illegible]
[illegible] 877-475-4799.

Serbo-Croatian: Ukoliko Vi ili neko kome Vi pomažete ima pitanje o Blue Cross Blue Shield of Arizona, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, nazovite 877-475-4799.

Thai: หากคณ หรอคนทคณกาลงชวยเหลอมคาถามเกยวกบ Blue Cross Blue Shield of Arizona
คณมสทธทจะไดรบความชวยเหลอและขอมลในภาษา ของคณไดโดยไมมคาใชจาย พดคยกบลาม โทร 877-475-4799